The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.

Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...

Enhanced monofocal IOLs may improve intermediate vision and preserve visual function in glaucoma patients. The study showed significant improvements in BCVA, RNFLT, and IOP for both enhanced and ...

FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the ...

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the ...

At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients ...

Please provide your email address to receive an email when new articles are posted on . Significantly more patients with multifocal IOLs were spectacle-free for near tasks than those with monofocal ...

BVI continues to execute its roadmap of IOL launches in Japan, the world's third-largest IOL-valued market 1 The PODEYE hydrophobic monofocal is perfectly suited to the Japanese market, where ...